8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


       Date of Report (Date of earliest event reported): January 13, 2002



                          MIRAVANT MEDICAL TECHNOLOGIES
             (Exact name of registrant as specified in its charter)



 Delaware                             0-25544               77-0222872
(State or other jurisdiction of     (Commission     (IRS Employer Identification
    incorporation)                  File Number)                 Number)

                           336 Bollay Drive
                       Santa Barbara, California             93117
               (Address of principal executive offices)    (Zip Code)
- ------------------------------------------------------------------------


Registrant's telephone number,  including area code: (805) 685-9880


                                       N/A
          (Former Name or Former Address, if Changed Since Last Report)






ITEM 5.  Other Events


     On January 13, 2002 we issued a press release announcing the results of our
Phase  III   clinical   trials  of  SnET2,   or  tin  ethyl   etiopurpurin,   an
investigational   drug  developed  for  the  wet  form  of  age-related  macular
degeneration, or wet AMD. The top line results of the trials indicate that SnET2
did not meet the primary efficacy endpoint in this study  population.  The press
release is attached as Exhibit 99 to this Form 8-K and is  incorporated  in this
report in its entirety.




Item 7. Exhibits


Exhibit
Number                                      Exhibit


Exhibit 99         Miravant Medical Technologies January 13, 2002 Press Release.










                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                            MIRAVANT MEDICAL TECHNOLOGIES


                                        By:      /s/ John M. Philpott
                                        -----------------------------------
                                              Name:  John M. Philpott
                                              Title: Chief Financial Officer

Date:    January 16, 2002






Exhibit
Number                                      Exhibit

Exhibit 99         Miravant Medical Technologies January 13, 2002 Press Release.

EX-99

Exhibit 99

MIRAVANT ANNOUNCES RESULTS OF PHASE III STUDY OF SnET2


SANTA BARBARA,  CA, January 13, 2002 - Miravant  Medical  Technologies  (Nasdaq:
MRVT) announced today the results of its phase III clinical trials of SnET2 (tin
ethyl  etiopurpurin),  an  investigational  drug  developed  for the wet form of
age-related  macular  degeneration (wet AMD). The top line results of the trials
indicate  that SnET2 did not meet the  primary  efficacy  endpoint in this study
population.

"We have always  recognized  the  challenges  of developing a treatment for this
serious  vision-threatening  disease," said Gary S. Kledzik,  Ph.D, chairman and
chief executive officer.  "We will be undertaking a full review of the data from
the phase III trials,  and will make future  development  decisions  about SnET2
after we have completed the additional analyses."

AMD is the leading  cause of severe  vision loss in people over 50 years of age.
The wet form of AMD is the more severe type,  affecting only 10 percent of those
with the disease,  but accounting for 90% of the blindness  caused by AMD. There
are approximately 400,000 new cases of wet AMD each year in the U.S. and Europe.

Miravant developed SnET2 in collaboration with Pharmacia  Corporation.  SnET2 is
an  investigational   photodynamic   therapy  (PDT)  for  sub-foveal   choroidal
neovascularization (CNV), also known as the wet form of AMD.

The phase III trials consist of two randomized, double-masked studies, enrolling
a total of 933  patients  with wet AMD.  Patients  were  treated with SnET2 (0.5
mg/kg and 0.75 mg/kg, placebo) and a diode laser using 664nm wavelength.

Miravant Medical  Technologies  specializes in both  pharmaceuticals and devices
for  photoselective  medicine.  The company is developing  PhotoPoint(tm) PDT in
ophthalmology, dermatology, cardiovascular disease and oncology.

The  statement  above  by Dr.  Kledzik  about  future  development  of  SnET2 is
forward-looking  and relates to our future plans,  objectives,  expectations and
intentions.  Our actual results may differ  materially  from those  described in
these  statements.  For instance,  the company may decide not to further develop
SnET2  for wet AMD or any  other  indication.  For a  discussion  of  additional
important risk factors that may cause our results to differ from those described
above,  please  refer to our  annual  report  on Form  10-K  for the year  ended
December  31,  2000 and other  quarterly  and  periodic  reports  filed with the
Securities and Exchange Commission.